Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-217,014 in Postherpetic Neuralgia
NCT00159640Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2004
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of PD-217014 in postherpetic neuralgia (PHN) (3 arms), sponsored by Pfizer. Primary endpoint: Mean change from baseline in numerical pain intensity rating scale score at 4 weeks. Started Feb 2004; status: terminated.
02
Drugs
PD-217014
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00159640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159640.